4 results
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
Primary:• To determine the safety and tolerability of FHD-286 when administered as an oral monotherapy in subjects with metastatic uveal melanoma (UM)• To identify the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of FHD-…
To assess the safety and feasibility of percutaneous CT-or ultrasound-guided RNT using the Oncosil* device in patients with non-progressive LAPC after induction chemotherapy treatment.
Primary Objective:To evaluate the efficacy of taldefgrobep alfa in participants who are already taking a stable dose of nusinersen or risdiplam or have a history of onasemnogene abeparvovec-xioi, compared to placebo, measured by change in the 32…